COMPASS Pathways plc · Healthcare · Medical Care Facilities
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$6.90
−$0.43 (−5.87%) 4:00 PM ET
After hours$6.96
+$0.06 (+0.87%) 4:27 AM ET
Prev closePrevC$7.33
OpenOpen$7.32
Day highHigh$7.39
Day lowLow$6.79
VolumeVol4,047,606
Avg volAvgVol3,631,668
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$783.27M
P/E ratio
-2.54
EPS
-2.72
Sector
Healthcare
AI report sections
BEARISH
CMPS
COMPASS Pathways plc
CMPS exhibits strong upward price momentum over the past year with the stock trading near the top of its 52-week range, supported by bullish technical signals and elevated volume. At the same time, fundamentals remain weak with sizeable losses, negative cash flow, and very high negative return ratios, while the valuation appears rich relative to book value. Short interest and recent news flow indicate heightened attention around positive late-stage clinical trial results, but also ongoing sensitivity to sentiment and data outcomes.
AI summarized at 6:09 PM ET, 2026-02-18
AI summary scores
INTRADAY:68SWING:74LONG:39
Volume vs average
Intraday (cumulative)
−22% (Below avg)
Vol/Avg: 0.78×
RSI
52.71(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.01 (Strong)
MACD: 0.02 Signal: 0.01
Short-Term
+0.09 (Strong)
MACD: 0.27 Signal: 0.19
Long-Term
+0.09 (Strong)
MACD: 0.38 Signal: 0.29
Intraday trend score
34.32
LOW34.32HIGH57.32
Latest news
CMPS•12 articles•Positive: 7Neutral: 0Negative: 0
PositiveBenzinga• Prnewswire
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.
COMP360 achieved two positive Phase 3 trials with highly statistically significant results (p<0.001); 39% of participants achieved clinically meaningful depression reduction; submitted rolling submission request to FDA; durable effects observed through 26 weeks.
PositiveThe Motley Fool• Howard Smith
Why Did Compass Pathways Stock Rocket Higher Today?
Compass Pathways stock surged 44% after announcing positive Phase 3 clinical trial results for COMP360, its psilocybin-based treatment for treatment-resistant depression. The company plans to submit a New Drug Application (NDA) to the FDA by the end of 2024, with trials involving over 1,000 participants showing statistically significant and clinically meaningful results.
CMPSpsilocybin therapytreatment-resistant depressionPhase 3 clinical trialsFDA approvalbiotech stockCOMP360New Drug Application
Sentiment note
Stock surged 44% on successful Phase 3 trial results showing statistically significant outcomes for psilocybin treatment. Company plans NDA submission to FDA by end of year, representing a major milestone in the drug approval process for a treatment addressing an underserved patient population with limited options.
PositiveThe Motley Fool• Eric Volkman
Why Compass Pathways Stock Was a Double-Digit Winner This Week
Compass Pathways, a U.K.-based biotech company focused on psilocybin, has completed dosing in a late-stage clinical trial for its synthesized psilocybin treatment, COMP005. The company is testing the treatment on patients with moderate to severe depression who have not responded to previous treatments. Investors are hopeful for the success of this trial, as the field of psychedelic medicine is seen as having significant potential.
The article highlights Compass Pathways' progress in its late-stage clinical trial for a psilocybin-based treatment, which is seen as a significant milestone in the company's mission to address the unmet need in treatment-resistant depression. The positive sentiment is based on the company's advancement in this trial and the potential of the psychedelic medicine field.
PositiveGlobeNewswire Inc.• Delveinsight
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight
The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.
COMPASS Pathways is mentioned as a company developing a promising therapy (COMP360) for treatment-resistant depression.
PositiveGlobeNewswire Inc.• Globe Newswire
Compass Pathways to participate in three investor conferences in September
Compass Pathways, a biotechnology company focused on mental health, announced its participation in several investor conferences in September 2024, including fireside chats and investor meetings.
The article highlights Compass Pathways' participation in investor conferences, which suggests the company is actively engaging with the investment community and is likely making progress in its mental health-focused initiatives.
PositiveInvesting.com• Professor Ari Zoldan
4 Psychedelic Stocks to Consider as Clinical Trials Heat up
Several biotechnology firms have psychedelic treatments in development, with promising results from clinical trials. The psychedelic market is expected to grow significantly, and most investors are favorable towards psychedelic stocks.
ATAICMPSIXHLMNMDpsychedelic stocksclinical trialsbiotechnologymental health
Sentiment note
Compass Pathways is conducting clinical trials for its psilocybin-based treatment for treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa, with positive results reported.
PositiveInvesting.com• Emilio Ghigini
Compass Pathways initiated at 'Outperform' by RBC, cites $2.3B revenue potential - Investing.com
RBC Capital initiated coverage on Compass Pathways with an Outperform rating and a $23 price target, citing a high likelihood of positive phase III trial results for its psilocybin-based treatment for treatment-resistant depression and a potential peak revenue of $2.3 billion.
RBC Capital expects positive phase III trial results and significant revenue potential for Compass Pathways' psilocybin-based treatment for treatment-resistant depression.
UnknownGlobeNewswire Inc.• Compass Pathways
Compass Pathways appoints Lori Englebert as Chief Commercial Officer
LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company’s New York City office.
CMPS earnings call for the period ending March 31, 2024.
CMPSearningscall-transcripts
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
